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ABSTRACT 
Background:  
 
Acute biliary sepsis which includes Acute cholecystitis and Acute Cholangitis 
are life threatening surgical emergencies which needs early recognition and 
prompt institution of appropriate management strategies.Except for some well 
known clinical signs like Murphy’s sign and Charcot’s triad there are no well 
defined criteria for the diagnosis of above said biliary infections.Tokyo 
Guidelines 2013 is expert panel formulated Diagnostic and severity 
assessment criteria guidelines  is the only guidelines available till date which 
aids in the diagnosis and management of the same.More number of patients 
can be  diagnosed at an early stage of infection and appropriate treatment 
instituted at the earliest by using this guidelines ,thus avoiding any foreseen 
complications.In this study,we have assessed the feasibility of using TG 13 
guidelines in diagnosing and managing acute biliary infections in Stanley 
medical college. 
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OBJECTIVE:  
This study sought to analyse  the outcome of managing acute biliary sepsis 
And comparing it in lines with TG 13 Guidelines.  
 
MAIN OUTCOME MEASURES:  
 
The Pattern of presentation,clinical features and contributing factors of Acute 
cholecystitis and Acute Cholangitis. 
 
STUDY DESIGN:       Descriptive  study.  
 
SETTING:                   Department of General surgery 
                                    Govt. Stanley Hospital ( GSH ) a tertiary hospital in  
                                    TAMILNADU.  
 
STUDY DURATION:  JUNE 2016 TO SEPTEMBER 2016.  
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                       METHODS AND MATERIALS  
 
Patients who had been diagnosed as a case of acute Cholecystitis and acute 
cholangitis were followed up and assesed using the TG 13 guidelines criteria 
and the outcomes were analysed. 
 
The efficacy of Using the guidelines in our setup and reproducibility of 
guideline demanding parameters were analysed that were appropriate in our 
setup. 
 
Clinical details and lab and imaging findings were recorded using a well 
detailed clinical proforma that included detailed description of analysis of a 
case of acute cholecystitis and cholangitis. Also other contributing 
factors,clinical patterns ,presentation ,treatment outcomes were analysed in 
detail.  
Data analysis and master charting was done using Microsoft Excel software 
And the results interpreted. 
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RESULTS: 
 
Acute Cholecystitis with most common etiology being gallstone disease is 
more common in males (56%),While Acute cholangitis is more common 
among elderly females.(58%).> 52 % patients diagnosed with Acute 
cholecystitis presented to us only after >72 hours of symptom onset. 43 %  
of  cholecystitis  and  > 50% cholangitis patients  were Diabetics Under 
treatment for the same. Diabetic Males more than 50 years of age with 
duration of diabetes less than 5 years had increased incidence of 
cholecystitis and present  with a higher grade. 
 
 
Keywords : Tokyo guidelines, acute biliary sepsis, diagnostic criteria 
                    Early cholecystectomy 
 
.  
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                                 INTRODUCTION  
 
 Acute cholangitis and Acute  cholecystitis require appropriate 
treatment in the acute phase. Severe acute cholangitis may result in 
early Mortality and Morbidity if appropriate medical care is Delayed in 
the acute phase.  
 
 Before the publication of the Tokyo Guidelines for the management of 
acute cholangitis and cholecystitis (TG07) in January 2007 ,which 
consequently was  updated in 2013 there were no practical guidelines 
throughout the world primarily targeting the treatment of acute 
cholangitis and cholecystitis. 
 
 TG13 Diagnostic Criteria of Acute Cholangitis and Cholecystitis  are 
criteria to establish the diagnosis when cholestasis and inflammation 
based on clinical signs or blood tests in addition to biliary 
manifestations based on imaging are present. 
 
 TG13 guidelines also encompasses a severity assessment criteria based 
on which patients can be divided into groups which are then managed 
accordingly as per the severity criteria. 
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 It allows for  early  diagnosis and easy management of patients and to 
determine the necessity for early biliary drainage in case of cholangitis 
and early cholecystectomy in case of cholecystitis which are vital life 
saving measures in view of these dreaded biliary tract infections.  
 
  
 
  
  
 
 
AIM OF THE STUDY 
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                                    AIMS AND OBJECTIVES 
 
•  To study on the clinical patterns ,presentation of Acute Biliary 
Infections @ stanley medical college. 
 
• To assess feasibility of application & the efficacy of  TG-13  
guidelines criteria and  norms  in  our  setup. 
 
• To analyse the outcomes of Current  treatment trends among 
the study population in our setup. 
 
  
REVIEW OF 
LITERATURE 
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                                REVIEW OF LITERATURE 
 
EMBRYOLOGY OF BILIARY TRACT: 
During the fourth week of gestation. A bud arises off the ventral wall of 
the primitive foregut,which eventually forms the duodenum.The liver 
diverticulum initially breaks into cranial and caudal portions-the cranial 
portion becoming the intrahepatic bile ducts and the caudal portion forming 
the gallbladder and the cystic duct. 
By the fifth week of intrauterine life,the cells between the liver bud and 
the remaining foregut proliferate to form a primitive bile duct. The common 
bile duct becomes occluded with epithelial cell Proliferation as it elongates 
and by the end of 5th week it recanalises moving distally towards the 
gallbladder which remains solid until 12th week .Failure to recanalize is 
attributed to the pathogenesis of biliary atresia. 
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ANATOMY OF BILIARY TREE: 
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                       COMPONENTS OF THE BILIARY TREE : 
 
 
1. RIGHT AND LEFT HEPATIC DUCTS 
 
 
2. COMMON HEPATIC DUCT 
 
 
3. GALL BLADDER  
 
 
4. CYSTIC DUCT 
 
 
5. COMMON BILE DUCT 
 
 
6. AMPULLARY REGION 
 
 
 
 
 
GALL BLADDER : 
 
The gallbladder is situated on the undersurface of the anterior inferior sector 
(Segment V) of the right lobe of the liver. Though often densely adherent, it is 
separated from the liver parenchyma by the cystic plate, a layer of connective 
tissue arising from Glisson’s capsule and in continuity with the hilar plate at 
the base of Segment IV. 
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Dimensions and Capacity 
The gall bladder is 7 to 10 cm long, 3 cm broad at its widest part, and  about 
30 to 50 ml in capacity. 
Parts 
The gall bladder is divided into: 
1. The fundus, 
2. The body, and 
3. The Infundibulum 
4. The Neck 
                                 
                                                         
Variations in gallbladder anatomy are rare. 
These variations include : 
(a) bilobed  or double gallbladders,  
(b) septated gallbladders, or  
(c) gallbladder diverticula 
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The fundus projects beyond the inferior border of the liver, in the angle 
between the lateral border of the right rectus abdominis and the ninth costal 
cartilage. It is entirely surrounded by peritoneum, and is related anteriorly to 
the anterior abdominal wall, and posteriorly to the beginning of the transverse 
colon. 
 
The body lies in the fossa for the gall bladder on the liver. The upper narrow 
end of the body is continuous with the neck at the right end of the porta 
hepatis. The superior surface of the body is devoid of peritoneum, and is 
adherent to the liver. The inferior surface is covered with peritoneum, and is 
related to the beginning of the transverse colon and to the first and second 
parts of the duodenum. 
 
The neck is the narrow upper end of the gall bladder. It is situated near the 
right end of the porta hepatis. It is continuous with the cystic duct. Its junction 
with the cystic duct is marked by a constriction. The mucous membrane of the 
neck is folded spirally to prevent any obstruction to the inflow or outflow of 
bile. The posteromedial wall of the neck is dilated outwards to form a pouch 
called the Hartmann’s pouch which is directed downwards and backwards. 
Gall stones may lodge in this pouch. 
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CYSTIC DUCT: 
 
The cystic duct arises from the infundibulum of the gallbladder and runs 
medial and inferior to join the common hepatic duct. The cystic duct is 
typically 1-3 mm in diameter and can range from 1 mm to 6 cm in length 
depending upon its union with the common hepatic duct. The mucous 
membrane of the cystic duct forms a series of 5 to 12 crescentic folds, 
arranged spirally to form the so-called spiral value of Heister. This is not a 
true valve. 
 
 
Cystic duct abnormalities are uncommon and include  
a) double cystic ducts (very rare),  
b)  aberrant cystic duct entry sites, and  
c)  aberrant cystic duct union with the common hepatic duct. 
 
 
Aberrant entry points for the cystic duct include a low entry into the common 
hepatic duct retroduodenal or retropancreatic and anomalous entry into the 
main right hepatic duct or sectoral duct. 
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         Common Bile Duct : 
Bile duct is formed by the union of the cystic duct and 
         common hepatic duct near the porta hepatis.  
          It is 8 cm long and  has a diameter of about 6 mm. 
         Course : 
The bile duct runs downwards and backwards, first in the free margin of the 
lesser omentum, supraduodenal  part; then behind the first part of the 
duodenum  the retroduodenal part; and lastly behind, or embedded in, the 
head of pancreas infraduodenal part. Near the middle of the left side of the 
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second part of the duodenum it comes in contact with the pancreatic duct and 
accompanies it through the wall of the duodenum, the intraduodenalpart. The 
course of the duct through the duodenal wall is very oblique.Within the wall 
the two ducts usually unite to form the hepatopancreatic ampulla, or ampulla 
of Vater. 
The distal constricted end of the ampulla opens at the summit of the major 
duodenal papilla 8 to 10 cm distal to the pylorus. 
 
AMPULLARY REGION 
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The terminal part of the bile duct is surrounded just above its junction  with 
the pancreatic duct by a ring of smooth muscle that forms  the sphincter 
choledochus (choledochus = bile duct). This sphincter is always present. It 
normally keeps the lower end of the bile duct closed (Fig. 22.7). As a result, 
bile formed in the liver keeps accumulating in the gallbladder and also 
undergoes considerable concentration. When food enters the duodenum, 
specially a fatty meal, the sphincter opens and bile stored in the gall bladder is 
poured into the duodenum. Another less developed sphincter, which is usually 
but not always present around the terminal part of the pancreatic duct is the 
sphincter pancreaticus. A third sphincter surrounds the hepatopancreatic 
ampulla and is called the sphincter ampullae or sphincter of Oddi. 
 
BLOOD SUPPLY OF THE BILIARY TREE : 
The cystic artery is the chief source of the blood supply, and is distributed to 
the gall bladder, the cystic duct, the hepatic ducts and the upper part of the bile 
duct.Several branches from the posterior superior pancreaticoduodenal artery 
supply the lower part of the bile duct.The right hepatic artery forms a minor 
source of blood supply to the middle part of the bile duct.The cystic artery 
usually arises from the right hepatic artery, passes behind the common hepatic 
and cystic ducts, and reaches the upper surface of the neck of the gall bladder, 
where it divides into superficial and deep branches. 
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FUNCTIONS OF GALLBLADDER : 
 
 Storage of bile, and its release into the duodenum when required. 
 
 Absorption of water, and concentration of bile.  
 
 The normal gall bladder also absorbs small amounts of a loose    
     bile salt-cholesterol compound. When the gall bladder is    
     inflamed, the concentration function becomes abnormal and the     
     bile salts   alone are absorbed leaving cholesterol behind.  
 
  It regulates pressure in the biliary system by appropriate  dilatation or 
contraction. Thus the normal, choledochoduodenal   mechanism is 
maintained. 
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PHYSIOLOGY OF BILE: 
Volume : 800 to 1,200 mL/day 
Reaction : Alkaline 
pH : 8 to 8.6 
Specific gravity : 1.010 to 1.011 
Color : Golden yellow or green. 
COMPOSITION OF BILE 
Bile contains 97.6% of water and 2.4% of solids. Solids 
include organic and inorganic substances.  
SECRETION OF BILE 
Bile is secreted by hepatocytes. The initial bile secreted by hepatocytes 
contains large quantity of bile acids, bile pigments, cholesterol, lecithin and 
fatty acids. From hepatocytes, bile is released into canaliculi.  From here, it 
passes through small ducts and hepatic ducts and reaches the common hepatic 
duct. From common hepatic duct, bile is diverted either directly into the 
intestine or into the gallbladder. Sodium, bicarbonate and water are added to 
bile when it passes through the ducts. These substances are secreted by the 
epithelial cells of the ducts. Addition of sodium, bicarbonate and water 
increases the total quantity of bile. 
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 STORAGE OF BILE 
Most of the bile from liver enters the gallbladder, where it is stored. It is 
released from gallbladder into the intestine whenever it is required. When bile 
is stored in gallbladder  it undergoes many changes both in quality and 
quantity  such as: 
 
1. Volume is decreased because of absorption of    a large amount of water and 
electrolytes (except calcium and potassium) 
 
2. Concentration of bile salts, bile pigments, cholesterol,  fatty acids and 
lecithin is increased because of absorption of water and electrolytes. 
 
3.  The pH is decreased slightly. 
 
4.  Specific gravity is increased. 
 
5.  Mucin is added to bile. 
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REGULATION OF BILE SECRETION: 
Bile secretion is a continuous process though the amount  is less during 
fasting. It starts increasing after meals and continues for three hours. Secretion 
of bile from liver and release of bile from the gallbladder are influenced by 
some chemical factors, which are categorized into three groups: 
1. Choleretics 
2. Cholagogue 
3. Hydrocholeretic agents. 
 Choleretics 
    Substances which increase the secretion of bile from 
    liver are known as choleretics. 
    Effective choleretic agents are: 
     i. Acetylcholine 
    ii. Secretin 
   iii. Cholecystokinin 
   iv. Acid chyme in intestine 
    v. Bile salts. 
  Cholagogues 
   Cholagogue is an agent which increases the release of 
   bile into the intestine by contracting gallbladder 
  Common cholagogues are: 
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  i. Bile salts 
 ii. Calcium 
iii. Fatty acids 
iv. Amino acids 
 v. Inorganic acids 
   All these substances stimulate the secretion of 
   cholecystokinin, which in turn causes contraction of 
   gallbladder and flow of bile into the intestine. 
 
 
 
 Hydrocholeretic Agents 
    Hydrocholeretic agent is a substance which causes  the secretion of bile    
from liver, with large amount of water and less amount of solids.          
Hydrochloric acid is a  hydrocholeretic agent. 
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PATHOPHYSIOLOGY OF GALLSTONES: 
 
Definitions 
 
Gallstone is a solid crystal deposit that is formed by cholesterol, calcium ions 
and bile pigments in the gallbladder or bile duct. Cholelithiasis is the presence 
of gallstones in gallbladder. Choledocholithiasis is the presence of gallstones 
in the bile ducts. 
 
Pathogenesis 
I. Metabolic: 
 Cholesterol is synthesised in liver. Its solubility is determined  by relative 
concentration of cholesterol, bile salts and lecithin. Altered levels of 
cholesterol, lecithin, and  bile salts in bile reduces the micelle concentration in 
 the bile leading to precipitation of insoluble cholesterol,  hence, the stone 
formation (Lithogenic bile). 
 
 Normal ratio of bile salt and lecithin to cholesterol is  25:1. Ratio below      
         13:1 leads to precipitation of cholesterol.  Insoluble cholesterol is within   
         the soluble micelle which is formed by lecithin and bile salts. If   
         cholesterol  component increases bile gets supersaturated and inadequate 
        micelle makes insoluble cholesterol to undergo crystallisation and    
         cholesterol monohydrate stone formation  
        (Admiron’s triangular hypothesis). 
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 Some cholesterol remains as bilayered lipid vesicles  which are soluble. A 
specific heat labile glycoprotein in  bile induces cholesterol monohydrate 
crystal formation in the vesicle and causes their aggregation. It is called 
      as nucleation. 
 
 Eventual precipitation and stone formation occurs by infection/infestation; 
pancreatic fluid reflux into CBD  causing conversion of toxic lecithin to 
lysolecithin which is also toxic (causes supersaturated bile); bile stasis or 
altered enterohepatic circulation. 
   
 
       Any condition which either increases the cholesterol  secretion in the    
      bile or reduces the bile salt concentration causes cholesterol stone  
      formation. Old age; OCP; obesity; clofibrate may increase cholesterol    
      secretion. Oestrogen, ileal resection and cholestyramine reduce 
       the bile salt concentration. 
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 Chenodeoxycholic acid and ursodeoxycholic acid  prevent cholesterol    
          stone formation by maintaining bile acid pool; reducing cholesterol    
          synthesis and secretion;  converting supersaturated bile into normal bile. 
 
         II. Infections and Infestations: 
 
      Bacteria like E. coli, Salmonella, 
       Parasites like Clonarchis sinensis and Ascaris lumbricoides 
       are often associated in the formation of Gallstones 
 
          III.  Bile stasis: 
              Occurs due to estrogen therapy, pregnancy,vagotomy and in      
              patients who are on long term intravenous   fluids or TPN. 
 
           IV. Increased bilirubin production due to any of the causes 
      of haemolysis as in hereditary spherocytosis, sickle cell 
       anaemia, thalassaemia, malaria, cirrhosis. Here pigment 
       stones are common. 
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Effects of the Gallstones: 
 In the gallbladder 
a.   Silent asymptomatic stones occurs in 10% of males and 
       20% of females. 
b. Biliary colic with periodicity, severe within hours after  meal 
 (commonest presentation). Biliary colic is spasmodic  pain often severe, 
 in right upper quadrant and epigastrium  radiating to chest, upper back  
 and shoulder. It is self-limiting, recurs unpredictably, often precipitated by 
      a fatty/heavy meal. Fever and increased WBC count may be observed. 
 
  iii. Acute cholecystitis. 
  iv. Chronic cholecystitis. 
   v. Empyema gallbladder. 
  vi. Perforation causing biliary peritonitis or pericholecystitic 
       abscess. 
 vii. Mucocele of gallbladder. 
 viii. Limey gallbladder. 
  ix.  Carcinoma gallbladder. 
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In the CBD 
 Secondary CBD stones (occurs in 10% of gallstones). 
 Acute Cholangitis. 
 Acute Pancreatitis. 
 Mirizzi syndrome (compression of CBD by stone from 
    cystic duct or cholecysto-choledochal fistula). 
 
 
 In the intestine: 
  Cholecystoduodenal fistula causing gallstone ileus and so intestinal    
  obstruction,by obstruction of small bowel  at the ileo-caecal junction. 
 
Diagnosis of Gallstone Disease: 
          Presence of gallstone is diagnosed by ultrasound scanning and 
cholangiography. Cholangiography is the radiological study of biliary ducts 
after the administration of a contrast medium. 
It is now more common to use Contrast enhanced CT scan of the  
Abdomen and pelvis to  visualise the Gallstones and CBD stones. 
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The Next Recent Modality of use is 
Magnetic Resonance Cholangio Pancreatography(MRCP). 
It is an excellent modality to map the pathology in the biliary tree 
Whether it be gallstones or carcinoma or Stricture  involving the 
Biliary tree. It has the advantage of non radiating and non invasive 
Modality. 
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Endoscopic Retrograde Pancreatico  Cholangiography(ERCP) is 
Vital diagnostic as well as therapeutic tool in evaluating and treating 
Distal biliary tree impacted stones or growth. 
It has an added advantage of being therapeutic 
also. Endoscopy  guided removal of stone and sphincterotomy can  
be done in the same sitting as a single procedure. 
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INFECTIONS OF THE BILIARY TREE : 
 
ACUTE CHOLECYSTITIS : 
 
Acute Cholecystitis is an acute abdominal emergency that is usually a result of 
gallbladder outlet being obstructed due to some etiology leading to bile stasis 
and infection of the retained bile & clinically patient presenting with Fever, 
upper abdominal pain and a palpable tender Gall Bladder. 
 
Classification: 
1. Acute calculous cholecystitis. 
2. Acute acalculous cholecystitis 
 
Pathogenesis of Acute Cholecystitis: 
Stone causes obstruction at Hartmann’s pouch or in cystic duct.  Obstruction 
causes stasis, oedema of the wall, bacterial infection,  acute cholecystitis and 
its effects. Impacted stone also causes  mucosal erosion allowing bile salts to 
act over the submucosal tissues  as bile is toxic to these tissues. It leads into 
necrosis, further infection  and often perforation of the gallbladder usually at 
Hartmann’s pouch. 
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Clinical Features 
Sudden onset of pain in the right hypochondrium, with 
tenderness, guarding, and rigidity. 
Palpable, tender, smooth, soft gallbladder. 
Area of hyperaesthesia between 9th and 11th ribs posteriorly 
on the right side (Boas’s sign). 
Jaundice may/ may not be present. 
Fever, nausea, palpable tender mass in GB region (25%). 
Tachycardia and toxic features. 
 
MURPHY’S SIGN: It is a characteristic clinical sign that can be elicited in a 
patient with inflamed Gall Bladder.With a palpating hand over the gallbladder 
point in the Right Hypochondrium when the patient is asked to take a deep 
breath,there is a characteristic inspiratory catch which is classic Murphy’s 
sign. 
The same can be elicited in the patient while doing an Ultrasound  
This is called as ULTRASONOGRAPHIC MURPHY’S SIGN. 
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VARIANTS OF ACUTE CHOLECYSTITIS: 
 
Acute Cholecystitis can present clinically as variant forms which are distinct 
in their own type of presentation and specific age group and  
Severity of the disease and significantly decide the outcomes . 
 
Variants include: 
 
 Acute Emphysematous Cholecystitis which presents in older age group and 
more commoner among diabetics and immunocompromised .It is caused 
by gas forming organisms in pathogenesis namely Clostridia.This clinical 
variant needs early recognition and early surgical treatment as delay in 
diagnosis and treatment leads to complications and significant increase in 
mortality and morbidity. 
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 Acute Gangrenous Cholecystitis: 
            This clinical variant of acute cholecystitis is characterized by the 
presence of early necrosis of gallbladder wall and early perforation of gall 
bladder resulting peritonitis and sepsis.This also needs prompt recognition 
and early treatment. 
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     Empyema Gallbladder:   
 
This variant of acute cholecystitis is  more aggressive variety and is 
charcterised by distension of gallbladder with acute inflammatory pus as a 
result of more aggressive course of infections.Empyema Gallbladder 
demands early surgical treatment as this variant is unlikely to respond to 
conventional antibiotic therapy. 
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Differential diagnosis to be considered while suspecting ACUTE 
CHOLECYSTITIS. 
 Duodenal ulcer perforation. 
 Acute pancreatitis. 
 Acute appendicitis. 
 Acute pyelonephritis. 
 Acute Hepatitis. 
 Lobar pneumonia, myocardial infarction. 
 
 
DIAGNOSIS:  
Acute Cholecystitis is an acute surgical emergency.Diagnosis made with  
Help of clinical ,imaging and lag findings after exclusion of other     
possible differentials as discussed above. 
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     MANAGEMENT: 
Acute Cholecystitis is Managegd by Surgery which can be either early or can 
be Delayed after the initial inflammatory surge has settled.Appropriate 
sensitive IV antibiotics are instituted targeting the most common flora of the 
biliary tract namely Gram negative enterococci such as  Eschierichia 
Coli.,Klebsiella species ,Proteus and others. Early surgical treatment can be 
accomplished by Laparascopic cholecystectomy or Conventional open 
cholecystectomy. Sometimes a even conservative surgical technique such as 
subtotal cholecystectomy may also be done.  
 
CTCCCT PICTURE  SHOWING DISTENDED 
GALLBLADDER AND VISUALISATION 
OF RADIOOPAQUE GALLSTONE AT 
THE NECK 
G 
GALL 
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DVV           DISTENDED GALLBLABBER 
                 WITH  GB WALL THICKENING  
                 IN CT SCAN. 
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ACUTE CHOLANGITIS: 
Acute bacterial cholangitis is a serious life-threatening emergency caused by 
infection of an obstructed biliary tract. The systemic manifestations result 
from bacteraemia. 
The most common obstructing agent is an occluding 
stone in the common bile duct, followed by bile duct strictures (including 
sclerosing cholangitis) and, less commonly, tumours of the bile ducts, 
pancreatic head and periampullary lesions. Cholangitis may also complicate 
bilioenteric anastomoses, spontaneous bilioenteric fistulae, cystic disease of 
the biliary tract and duodenal diverticulae. Cholangitis may also occur 
following instrumentation of the biliary tract, e.g. after ERCP.  The infection 
is most commonly caused by Gram negative 
organisms.  
The classic triad of symptoms consists of  
 pain in the right hypochondrium,  
 intermittent fever and 
 jaundice  
(Charcot's Triad).  
Aside from toxicity, the high intermittent pyrexia is accompanied by severe 
rigors. The pain varies in intensity and may be severe. There is usually 
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tenderness in the right hypochondrium that, if marked, suggests the presence 
of abscess formation. Nausea and vomiting are frequent accompaniments. 
Hypotension is found in patients with severe cholangitis, when renal failure is 
usually present. The overall reported mortality of patients requiring urgent 
decompression for severe cholangitis is 15-20%. 
 
DIAGNOSIS:  
High index of clinical suspicion and imaging evidence of dilated biliary tree 
and stagnant bile is more in favour of Acute cholangitis.Lab parameters in the 
form of increased serum bilirubin And Serum Alkaline phosphatase  and total 
leucocyte count are all more in favour the Diagnosis. 
 
MANAGEMENT: 
In acute cholangitis in addition to clinical sepsis most of the patients present 
with multiple organ dysfunction and are in a state of shock. Treatment of 
Acute cholangitis is to be more focused on providing support for organ 
dysfunction in the form of intensive supportive care and definitive procedure 
to decompress the biliary tree is planned henceforth . 
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Decompression of the obstructed and dilated biliary tract is done 
By either surgically or percutaneous or endoscopic guided depending upon the 
status of the patient and the level of obstruction in the biliary tree.  
 
Appropriate IV antibiotics to be instituted depending the flora and septicaemia 
status of the patient.Organ dysfunction should be promptly addressed in a 
intensive care setting and close monitoring of vitals done. 
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TOKYO GUIDELINES 2013 IN MANAGEMENT OF ACUTE BILIARY  
INFECTIONS: 
 
In 2003,The Japanese society of hepato-pancreatic biliary surgery formed 
working group to formulate guidelines to diagnose and manage the acute 
biliary sepsis.As a result of which Tokyo guidelines 2007 was formulated 
dictating diagnostic criteria and severity assessment criteria for protocol based 
management of acute cholecystitis and acute cholangitis.There were few flaws 
and drawbacks in 2007 format,hence it was reworked upon and updated 
Tokyo guidelines was formulated in the year 2013. 
 
This Tokyo guidelines 2013 is the currently available only guidelines 
universally in the management of above said biliary infections. 
 
The guidelines not only aids in the diagnosis of Acute cholecystitis and Acute 
cholangitis but also offers a platform to assess the severity of the disease with 
which the patient presents to medical attention and guide appropriate 
treatment. 
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         TG 13 DIAGNOSTIC CRITERIA FOR ACUTE CHOLECYSTITIS  
A LOCAL SIGNS OF INFLAMMATION:  
A-1 Murphy’s sign  
A-2 Right upper quadrant pain/mass/tenderness  
B SYSTEMIC SIGNS OF INFLAMMATION:  
B-1 Fever  
B-2 Elevated CRP  
B-3 Elevated WBC counts  
C IMAGING:  
C-1 Thickening of Gallbladder > 5mm  
C-2 Enlarged Gallbladder  
C-3 Debris Echo  
C-4 Ultrasonographic’s Murphy’s Sign  
C-5 Gas imaging  
C-6 Pericholecystic fluid  
 
 
 
     SUSPECTED DIAGNOSIS:       One item in A + One item  in B 
 
     DEFINITE DIAGNOSIS     :      One item in A + One item  in B +C 
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       SEVERITY ASSESSMENT CRITERIA FOR ACUTE CHOLECYSTITIS: 
     GRADE III : ACUTE CHOLECYSTITIS + Any of following organ dysfunction : 
1. CVS Dysfunction: 
Hypotension requiring treatment with dopamine>/= 5µg/kg/min or 
                   any dose of Noradrenaline 
 
2 Neurological Dysfunction: 
Decreased level of consciousness 
 
3. Renal Dysfunction: 
Oliguria/ creatinine > 2 mg/dl 
 
4 Respiratory Dysfunction: 
PaO2/FiO2 ratio < 300 
 
5 Hepatic dysfunction 
PT-INR > 1.5 
 
6. Hematological Dysfunction: 
Platelet count < 1,00,000/mm 3 
 
Grade II: Presence of any of the following: 
1 Elevated WBC count > 18,000/mm3  
2 Palpable tender mass in Right upper Quadrant  
3 Duration of symptoms > 72 hours  
4 Marked local inflammation(gangrenous or emphysematous cholecystitis/pericholecystic 
or hepatic abscess/biliary peritonitis) 
 
 
      GRADE I: Does not meet the criteria of GRADE III/GRADE II.         
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                          TG 13 CRITERIA FOR DIAGNOSING ACUTE CHOLANGITIS 
 
A SYSTEMIC INFLAMMATION:  
A-1 Fever and /or shaking chills  
A-2 WBC Count < 4000 / >10000 cells/mm3 or 
CRP  .>/=    1mg/dl 
 
B CHOLESTASIS  
B-1 Jaundice (T.Bilirubin > 2mg/dl)  
B-2 Abnormal Liver function tests  
C IMAGING:  
C-1 Biliary dilatation  
C-2 Evidence of etiology on imaging 
(stricture/stone/stent) 
 
 
      SUSPECTED DIAGNOSIS : One item in A + One item in B 
 
      DEFINITE DIAGNOSIS      :One item in A  + One item in B + One Item in C 
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           SEVERITY ASSESSMENT CRITERIA FOR ACUTE CHOLANGITIS: 
      GRADE III : ACUTE CHOLANGITIS + Any of following organ dysfunction : 
1
. 
CVS Dysfunction: 
Hypotension requiring treatment with dopamine>/= 5µg/kg/min or 
                   any dose of Noradrenaline 
 
2 Neurological Dysfunction: 
Decreased level of consciousness 
 
3
. 
Renal Dysfunction: 
Oliguria/ creatinine > 2 mg/dl 
 
4 Respiratory Dysfunction: 
PaO2/FiO2 ratio < 300 
 
5 Hepatic dysfunction 
PT-INR > 1.5 
 
6
. 
Hematological Dysfunction: 
Platelet count < 1,00,000/mm 3 
 
Grade II: Presence of any of the following: 
1 Elevated WBC count > 12,000/mm3 & < 4000 cells /mm3  
2 High fever (>39 degree centigrade)  
3 Age > / = 75 years  
4 Hyperbilirubinemia (T.bilirubin >5 mg/dl)  
5 Hypoalbuminemia  (< Max upper limit value x 0.7)   
 
              GRADE I: Does not meet the criteria of GRADE III/GRADE II at Initial 
diagnosis        
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MANAGEMENT OF CHOLECYSTITIS ACCORDING TO TG 13 
GUIDELINES: 
Grade I (Mild) acute cholecystitis: Early laparoscopic cholecystectomy is 
the preferred procedure. 
 
Grade II (Moderate) acute cholecystitis: Early cholecystectomy is 
recommended in experienced centers. However, if patients have severe local 
inflammation, early gallbladder drainage (percutaneous or surgical) is 
indicated. Because early cholecystectomy may be difficult, medical treatment 
and delayed cholecystectomy are necessary. 
 
Grade III (Severe) acute cholecystitis:  
Urgent management of organ dysfunction and management of severe local 
inflammation by gallbladder drainage should be carried out. Delayed elective 
cholecystectomy should be performed when cholecystectomy is indicated.  
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GUIDELINE STRATEGY FOR MANAGING ACUTE 
CHOLECYSTITIS DEPENDING UPON THE GRADE OF THE 
DISEASE: 
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GUIDELINE STRATEGY FOR MANAGING ACUTE 
CHOLANGITIS  DEPENDING UPON THE GRADE OF THE 
DISEASE: 
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              RESULTS 
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LIST OF ANALYSIS IN ACUTE CHOLECYSTITIS: 
TOTAL NUMBER OF PATIENTS ANALYSED: 23 
1.Age wise incidence. 
2.Sex Distribution. 
3.Duration of Symptoms in the study group. 
4.Symptoms in the study group. 
5.Signs in the study group. 
6.Ultrasonogram findings in the study group. 
7.Biochemical Results in the study group. 
8.Incidence of Diabetes among study population. 
9. Etiology among study group. 
10.Pattern of Gallstone disease in study group. 
11.Analysis of the Grade of disease among the study group. 
12.Age vs Grade analysis in study group. 
13.Age vs sex correlation among study group.  
14.Duration of Diabetes vs Grade of disease. 
15.Age-grade-incidence of diabetes among study group. 
16.Analysis of management outcomes in Grade 1 cholecystitis. 
17.Analysis of management outcomes in Grade 2 cholecystitis. 
18.Complications in the study group. 
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                        AGE WISE INCIDENCE 
     
 
 
 
 
 
Incidence of acute cholecystitis follows common literature pattern of 
occurring in elderly patients above 50 years of age. 
<40 years 
17% 
40-50 
years 
26% 
>50 years 
57% 
INCIDENCE OF CHOLECYSTITIS 
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                                 SEX DISTRIBUTION 
 
 
 
 
 
 
  
  AA       ACUTE CHOLECYSTITIS HAD A HIGHER INCIDENCE IN 
MALES(65 %) IN OUR STUDY GROUP 
male, 15 
female, 8 
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         DURATION OF SYMPTOMS  
 
 
 
 
 
More than 52 % of the patients presented to medical attention after 
72 hours because of lack of awareness and early recognition both by 
patients and doctors. 
Invariably patient will be categorized as GRADE 2 
CHOLECYSTITIS 
 
 
 
 
 
<24 hours 
0% 
24-72 
48% >72 hours 
52% 
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SYMPTOMS IN STUDY GROUP 
 
 
 
 
 
   Acute onset Upper abdominal pain more over the Right 
Hypochondrium is  the predominant complaint and was the first to 
arise in the study  population.  
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   CLINICAL SIGNS AMONG THE STUDY POPULATION 
 
 
 
 
 
9 out of 13 patients had tenderness  in upper abdomen alone as the 
predominant Clinical sign on examination. Murphy’s sign alone was 
not seen in a single patient. 
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                     DIABETIC HISTORY 
 
 
 
 
 
 
43 % OF THE STUDY POPULATION WERE DIABETIC AND 
WERE UNDER TRETAMENT FOR THE SAME. 
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                             FEVER IN STUDY POPULATION 
 
   
 
 
 
 
  Nearly 50 % of the study group were afebrile  at the time of     
  presentation. 
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                                   TOTAL LEUCOCYTE COUNT    
 
                          
 
 
   
 
       More than 80 % of the study population had an elevated total 
Leucocyte count of more than 12000 cells/mm3. 
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More than 80 % of the study population had serum amylase level 
Above 40 IU/L. 
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More than 60 % of the study group had an elevated total Cholesterol 
level of more than 150 mg/dl. 
 
 
 
 
 
              
[71] 
 
 ULTRASONOGRAM  FINDING IN STUDY POPULATION 
 
 
 
 
Thickening of Gall bladder wall (65 %) was the most consistent 
Finding In ultrasonogram of the study population.Enlarged 
Gallbladder was the second most common finding that is attributed 
To Acute cholecystitis. 
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                           PATTERN OF GB STONE DISEASE 
 
     
 
 
              In most patients with Gallstones as detected etiology  Multiple GB    
  stones was more common .In patients with single Gallstone the 
  predominant site was neck of gallbladder. 
 
 
 
 
\ 
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                            GRADE OF CHOLECYSTITIS 
 
 
 
 
 
 
 
Grade 2 Cholecystitis was the most common Grade of disease of 
most patients in our study group.More than 50% of study population 
Had grade 2 disease at the time of presentation. 
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                            AGE VS GRADE DISTRIBUTION 
 
 
 
 
 
 
Patients  more than 50 years of age have a higher incidence of the 
disease,with the grade of cholecystitis higher at the time of 
presentation. 
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                      AGE AND SEX CO-RELATION 
 
 
 
 
 
 
 
Males more than 50 years of age are higher up in the incidence 
chart. 
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DURATION OF DIABETES WITH SEVERITY OF DISEASE 
 
 
                
          
 
 
 
Diabetics of less than 5 years of duration present more with the 
disease And also a higher grade at presentation. 
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               AGE –INCIDENCE OF DIABETES-GRADE OF DISEASE 
 
 
 
   
        
    
 
 
            Diabetic males above 50 years of age have a higher  Incidence of the 
            disease and with a higher grade at the time of presentation. 
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                MANAGEMENT OF GRADE 1  
                   ACUTE CHOLECYSTITIS  
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                                    GRADE 1 CHOLECYSTITIS 
                                   MANAGEMENT OUTCOMES 
 
                      TOTAL NUMBER OF PATIENTS : 10 
 
  
 
Most of Grade 1 patients(60 %)  were managed Conservatively with  
antibiotics and delayed surgery .  
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              AGE DISTRIBUTION OF SURGICAL PATIENTS IN 
                                     GRADE 1 CHOLECYSTITIS 
 
      
      In our  study,most of the surgical candidates of  Grade 1 disease 
were  of  younger age group. 
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                                       TIMING OF SURGERY IN 
                              GRADE 1 CHOLECYSTITIS PATIENTS 
   
       
 
Only 50 % of the surgical group were subjected to Early 
Cholecystectomy within 72 hours of presentation as dictated by the       
TG 13 guidelines. 
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                                    TYPE OF SURGERY 
                           GRADE 1 CHOLECYSTITIS PATIENTS
 
 
All patients in the early surgical group were attempted  Laparascopic 
Cholecystectomy which eventually was converted to open 
cholecystectomy because of intra-operative difficulty in dissecting 
the calot’s triangle. 
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               MANAGEMENT OUTCOMES OF GRADE 2  
                            ACUTE CHOLECYSTITIS 
 
  
          TOTAL NUMBER OF PATIENTS(GRADE 2) : 13 
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          TIMING OF CHOLECYSTECTOMY  IN GRADE 2  
                                  ACUTE CHOLECYSTITIS PATIENTS 
  
         
 
9 out of 13 patients  who had grade 2 disease were managed with 
Early cholecystectomy in our setup . 
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             TIMING OF SURGERY IN EARLY SURGICAL GROUP IN  
                                    GRADE 2 CHOLECYSTITIS 
 
       
 
        Only 2 patients out of 9 in early cholecystectomy group        
Had their surgery within 72 hours. Most patients were included in 
this group had  failed  Conservative line of management . 
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                                            TYPE OF SURGERY   
          GRADE 2 CHOLECYSTITIS -EARLY SURGICAL GROUP 
 
 
 
7 out of 9 patients were subjected to laparascopic cholecystectomy 
which eventually was converted to  Open cholecystectomy. None of 
the patients underwent laparascopic cholecystectomy in Grade   2 
disease. 
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INTRA-OP FINDINGS IN OPERATED GROUP OF 
PATIENTS 
 
 
    
        
 
 
Grade 2 Disease patients were difficult to manage intra-
operatively  With a myriad of findings intraoperatively. 
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   DISTENDED INFLAMMED  GALLBLADDER-INTRA-OP 
       
 
                         FROZEN CALOT’S TRIANGLE 
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POST-OPERATIVE COMPLICATIONS IN OPERATIVE GROUP 
 
 
 
 
 
Only one patient had post-operative surgical site Infection.One 
patient expired of sepsis. 
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         ANALYSIS  OF  MANAGEMENT     
                     OUTCOMES IN 
                ACUTE CHOLANGITIS 
 
 
 
      TOTAL NUMBER OF PATIENTS STUDIED : 9 
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                         AGE WISE DISTRIBUTION 
 
 
 
 
 
More than 50 % of the study population in the  Acute Cholangitis 
group were > 50 years of age. 
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                              SEX DISTRIBUTION 
 
 
 
 
 
 
56 % of  the cholangitis patients were females in our  Study which is 
on par with literature references. 
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                             CHARCOT’S TRIAD 
 
 
 
 
 
 
89 % patients in my study group had the characteristic  Charcot’s 
triad in Acute Cholangitis. 
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                         DIABETES MELLITUS 
 
 
 
 
 
 
More than 50 % of the patients in my study group  were  Diabetics 
and were in some form of treatment for the same 
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                  TOTAL LEUCOCYTE COUNT 
 
 
 
 
 
 
All patients in the study group had an elevated total Leucocyte count 
of more than 10000 one of the demanding criteria In TG13 
guidelines. 
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                      TOTAL BILIRUBIN LEVELS 
 
 
 
 
 
 
 
All patients had elevated Total bilirubin levels with most  commom 
range being  2mg/dl -10mg/dl. 
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            CAUSE FOR BILIARY TREE OBSTRUCTION 
 
 
 
 
 
 
Malignant obstruction of the biliary tree was the most  Common 
etiological agent.2nd common cause was gallstone Disease. 
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       GRADE OF CHOLANGITIS IN STUDY POPULATION 
 
 
 
 
 
 
 
60 % of the patients in my study group had Grade 2 disease or more 
at the time of  Presentation. 
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        MANAGEMENT  OUTCOMES IN 
         ACUTE CHOLANGITIS GROUP 
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                         BILIARY DRAINAGE 
 
 
 
 
6 out of 9 patients had biliary drainage done after  initial 
stabilisation and recovery. 
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                          TYPE OF BILIARY DRAINAGE 
 
 
 
 
Most common Drainage procedure was  Percutaneous Biliary 
drainage . 2  out of 6 patients were endoscopically drained. 
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          TIMING OF BILIARY DRAINAGE FROM DIAGNOSIS 
 
 
 
 
 
None of the patients among 6 patients who were subjected for 
biliary tract drainage were drained. In the initial 24 hours. 
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                          DISCUSSION 
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 Acute Biliary sepsis is more common in elderly patients aged more than 50 
years of age.Acute Cholecystitis with most common etiology being 
gallstone disease is more common in males (56%),While Acute cholangitis  
is more common among elderly females.(58%) 
 
 Acute cholecystits is most commonly caused by Gallstones,while Acute  
Cholangitis is most commonly caused by malignant growth causing    
obstruction to the biliary tract. 
 
 > 52 % patients diagnosed with Acute cholecystitis presented to us only 
after >72 hours of symptom onset,invariably these patients were 
categorized as Grade 2 as per TG 13 guidelines 
 
 Acute onset upper abdominal pain was the most common symptom in the 
study group and tenderness over the right hypochondrium was the most 
common clinical sign elicited among the study group. 
 
 43 %  of  cholecystitis  and  > 50% cholangitis patients  were Diabetics  
Under treatment for the same. 
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 Nearly  50 % of the patients in cholecystitis group were afebrile at the time 
of presentation. 
 
 > 80 % of the study population in cholecystitis group had an elevated 
leucocyte count of more than 12000 cells/mm 3 and Serum Amylase  
Levels more than 40 IU/L. 
 
 More than 65 % of the cholecystitis group had a thickened gallbladder wall 
of size more than 5 mm in the initial screening ultrasound which was the 
most consistent finding followed by an enlarged gallbladder. 
 
 57 % of patients with cholecystitis and 60 % of patients with cholangitis 
Were Grade 2 diseased as per TG 13 severity assessment criteria. 
 
 60 % of Grade 1 cholecystitis patients were managed conservatively and 
70% of  Grade 2 cholecystitis patients were managed surgically as the first 
Modality in the study group. 
 
 66 % of the cholangitis patients had biliary drainage with percutaneous 
Route being the most commonly used biliary drainage procedure and 
Only after 24 hours due to non availability of interventional radiologist 
and poor general condition. 
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 7 out of 9 patients of grade 2 cholecystitis who were managed with early 
surgery were proceeded with laparoscopic cholecystectomy which 
eventually got converted to open cholecystectomy in due course due ti 
intraoperative difficulty. 
 
 Only 2 out of 7 patients in the early surgical group in grade 2 cholecystitis 
group had their surgery within 72 hours of symptom onset. 
 
 
  Post-operative complications were minimal in the  operated cholecystitis  
group with wound infection occurring in one patient and one patient died 
postoperatively because of uncontrolled sepsis despite early treatment. 
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 CROSS COMPARISONS : 
 
 AGE-SEX IN CHOLECYSTITIS: 
       Males aged > 50 years of age had a higher incidence of acute                 
       cholecystitis 
 
 AGE-SEX-GRADE IN CHOLECYSTITIS: 
Males more than 50 years had a higher grade of disease at the time of 
presentation. 
 
 DURATION OF DIABETES –SEVERITY OF CHOLECYSTITIS: 
Diabetic Males more than 50 years of age with duration of diabetes less 
than 5 years had increased incidence of cholecystitis and presented with a 
higher grade. 
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                          CONCLUSION 
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 Elderly patients in the 5th decade with diabetes mellitus as co-
morbid illness are at high risk for acute biliary sepsis. Routine 
screening for contributing factors of the disease for these patients 
may be considered. 
 
 Early laparoscopic cholecystectomy can be considered within 72 
hours ,if patient is young and without any co-morbid illness. 
 
 TOKYO GUIDELINES 2013 is an appropriate tool that can be     
used in our setup without any fallbacks as most of parameters. In 
the guidelines can be analysed and reproduced in our       
population group. 
 
   Availability of trained radiologist/intervention radiologist in our 
  Setup needed to be overlooked as early biliary drainage is vital   
  in the outcome of cholangitis and makes us complete in adopting    
  the guidelines. 
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  A Large multicentre analytical study may be needed  to analyse 
the guideline demanding parameters and other factors that can be 
added positively as recommendations to the guidelines 
formulating committee. 
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                                     ANNEXURES 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
              
[115] 
 
                                                     PROFORMA 
A study on outcomes & efficacy in managing acute cholangitis & acute cholecystitis 
based on TG 13 Guidelines. 
Investigator: Dr.S.SIVAPRAGASH , PG 2nd year – MS (General Surgery) 
Guide: Prof. Dr. LALITHKUMAR, Chief, Unit S7 
• NAME :          SL. NO: 
• AGE /SEX:  
• ADDRESS WITH CONTACT NUMBER:  
• IP NO:  
• DATE OF ADMISSION:  
• DATE OF SURGERY:  
• DURATION OF SYMPTOMS: 
HISTORY OF PRESENTING ILLNESS:  
  
  
PAST HISTORY:  
   WHETHER A KNOWN CASE OF DM/HYPERTENSION/ASTHMA/TB/EPILEPSY/CARDIAC ILLNESS  
                H/O SIMILAR EPISODES IN THE PAST, IF ANY: 
 
CLINICAL EXAMINATION: 
GENERAL EXAMINATION:  TEMP:          P.R:       B.P:       R.R          WEIGHT    HEIGHT  
SYSTEMIC EXAMINATION: 
  CVS 
  RS 
PER ABDOMEN:     
  CLINICAL DIAGNOSIS: 
 
 
 
 
              
[116] 
 
BLOOD INVESTIGATIONS: 
HEMAT  
HB  
PCV  
RBC  
TC  
DC  
PLT  
ESR  
RBS  
 
 
CRP  
B.UREA  
S.CREAT  
S.Na+  
S.K+  
S.Cl-  
S.HCO3-  
LIVER FUNCTION TESTS:                             
T.BILIRUBIN  
 DIRECT BILIRUBIN  
AST  
ALT  
ALP  
S.ALBUMIN  
 
LIPID PROFILE :        T.Cholesterol:                    Triglyceride level:                          
IMAGING:                               CHEST X-RAY:                                                                ABDOMEN X-RAY:  
USG ABDOMEN: 
 
 
 
 
PT  
 INR  
              
[117] 
 
 
1. ANTIBIOTIC USED : 
 
2. DURATION OF ANTIBIOTICS: 
 
3.  SURGERY:    
 
DAY OF SURGERY FROM DIAGNOSIS: 
 
 
4.  TYPE OF SURGERY :  OPEN CHOLE                LAP CHOLE               LAP ---
OPEN      
 
 INTRA-OP: 
 
5.  COMPLICATIONS : 
 
6. OTHER INTERVENTIONS,IF ANY: 
 
 
7. POST –OPERATIVE PHASE:     ICU                   DAYS:                FEVER     
 
 
 
8. TRANSFUSIONS  : 
 
9. DURATION OF STAY IN HOSPITAL : 
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